Role of Cytochrome P450 2D6 (CYP2D6) *4 Polymorphism,in Malignant Breast Diseases

October 3, 2007 updated by: Mansoura University

Role of Cytochrome P450 2D6 (CYP2D6) *4 Polymorphism, Oxidative Stress and Ferretin in Benign and Malignant Breast Diseases

The aim of our study is to investigate the potential role of the CYP2D6*4 polymorphism in breast cancer and furthermore to assess the role of oxidative stress, antioxidant capacity and ferretin in pathogenesis of breast cancer in different CYP2D6*4 genotypes

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Breast cancer is the most common malignancy among women and the second highest cause of cancer death. Nevertheless most of the breast cancer is sporadic with no family history of the disease, Enhanced CYP2D6 activity has been related to malignancies of the bladder, liver, pharynx, and stomach and, especially, to cigarette-smoking-induced lung cancer. Data support that increased formation of reactive oxygen species (ROS) may play an important role in carcinogenesis Numerous in vitro experiments show that ROS damages DNA, inducing premutagenic modifications of nucleotides and promoting oxidation of proteins and lipid per oxidation The aim of our study is to investigate the potential role of the CYP2D6*4 polymorphism in breast cancer and furthermore to assess the role of oxidative stress, antioxidant capacity and ferretin in pathogenesis of breast cancer in different CYP2D6*4 genotypes.patients and methods : This study included 31 women admitted to the general surgery department, Mansoura University Hospital. group I consists of 15 women with benign breast lesion, group II composed of 16 women with cancer breast and 13 healthy women with matched age and clinically free were taken as a control group. DNA extraction and genotyping of cytochrome P450-2D6*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.Results homozygous genotype of 2D6*4 represent 56.25 %( 9/16) of breast cancer group with lower wild type (31.25%-5/16), while it represent 33.3 %( 5/15) of begnine breast lesion group and 15.3(2/13) of the control group. Where the wild type represent the majority of cases (61.15%-8/13) in the control group and 46.6%-7/15) in the begnine breast lesion group.

statistically significant increase in plasma ferretin and MDA mean levels in breast cancer group than begnine breast lesion and the control groups .Also, there is an increase in plasma total antioxidant activity in breast cancer group than the control group with nonstatistical difference between the breast cancer and the benign breast lesion groups .

Conclusion CYP2D6*4 genotype polymorphism interacting with plasma malondialdehyde (MDA) oxidative stress and plasma ferretin level may have a role in the pathogenesis of breast cancer

Study Type

Observational

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • Dakahlia
      • Mansoura, Dakahlia, Egypt, 35116
        • Mansoura Faculty of medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

33 years to 63 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • This study included 31 women admitted to the general surgery department, Mansoura University Hospital. group I consists of 15 women with benign breast lesion, group II composed of 16 women with cancer breast and 13 healthy women with matched age and clinically free were taken as a control group.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
I
group I of 15 women with benign breast lesion
Genetic: pcr and serum markers for breast cancer
DNA extraction and genotyping of cytochrome P450-2D6*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.
II
group II of 16 women with breast cancer
Genetic: pcr and serum markers for breast cancer
DNA extraction and genotyping of cytochrome P450-2D6*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.
III
13 women were taken as a control group
Genetic: pcr and serum markers for breast cancer
DNA extraction and genotyping of cytochrome P450-2D6*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mansoura University

Investigators

  • Principal Investigator: wagih m ghnnam, mansoura faculty of medicine general surgery department
  • Study Director: Aymen z El Samanoudy, mansoura faculty of medicine biochemistry department

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2006

Study Completion (Actual)

April 1, 2007

Study Registration Dates

First Submitted

October 3, 2007

First Submitted That Met QC Criteria

October 3, 2007

First Posted (Estimate)

October 4, 2007

Study Record Updates

Last Update Posted (Estimate)

October 4, 2007

Last Update Submitted That Met QC Criteria

October 3, 2007

Last Verified

October 1, 2007

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Role of cytochrome P450 2D6

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on pcr and serum markers for breast cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe